摘要
目的:观察白三烯受体拮抗剂在儿童支气管哮喘长期治疗中的作用。方法:根据不同的长期治疗方案,将79例轻、中度支气管哮喘患儿分为三组,35例单纯吸入布地奈德气雾剂为治疗A组,33例口服孟鲁司特钠片为治疗B组,11例单纯中医治疗作为对照组,观察各组临床疗效和肺功能指标变化,并进行统计学分析。结果:治疗A组和治疗B组的临床疗效分别与对照组比较,χ2=22.62、16.05,差异有统计学意义(P<0.001),治疗组之间比较,差异无统计学意义(P>0.05)。两个治疗组治疗前后肺功能比较,差异有统计学意义(P<0.01)。结论:在轻、中度支气管哮喘的治疗中,白三烯受体拮抗剂与吸入糖皮质激素同样可以取得满意的疗效且无明显不良反应。
Objective： To observe the effect of long term therapy of leukotriene receptor antagonist in asthmatic children. Methods： Based on different plans of long term treatment, 79 children with mild or moderate asthma were divided into three groups. Thirty-five children with asthma who received only inhaled budesonide served as treatment group A. Other thirty-three children in treatment group B were treated with orally montelukast. Eleven children, who abandoned treatment plans for one or another reason, served as a control group. Clinical results between three groups and the changes of pulmonary function were compared. Results： The therapeutic effect of two treatment groups was compared with that of control group. The results are χ^2= 22.62, 16.05 respectively （ P 〈 0. 001 ）. There was no significant difference in two treatment groups （ P 〉 0.05）. There was significant difference in the change of pulmonary function in the two treatment groups before and after treatment （P 〈 0.01 ）. Conclusions： Leukotriene receptor antagonist, as well as inhaled budesonlde, is helpful in treating mild or moderate asthma and no significant adverse events are found.
出处
《儿科药学杂志》
CAS
2006年第5期32-34,共3页
Journal of Pediatric Pharmacy
关键词
儿童
哮喘
白三烯受体拮抗剂
孟鲁司特
肺功能
Children
Asthma
Leukotriene receptor antagonist
Montelukast
Pulmonary function
